Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 18/20 | 1.00 |
| ▸ | CA9 | Q16790 | 17/20 | 1.00 |
| ▸ | ELANE | P08246 | 1/20 | 0.69 |
| ▸ | CA2 | P00918 | 7/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30834902 | 1.00 | CA12 (1.00) | CA12CA9ELANECA2ALDH1A1 | |
| SCHEMBL698407 | 0.86 | CA9 (1.00) | CA12CA9ELANECA2ALDH1A1 | |
| SCHEMBL6958970 | 0.83 | CA12 (0.71) | CA12CA9ELANECA2CA1 | |
| SCHEMBL7903703 | 0.83 | CA9 (1.00) | CA12CA9ELANECA2ALDH1A1 | |
| SCHEMBL1758371 | 0.82 | CA9 (1.00) | CA12CA9ELANECA2ALDH1A1 | |
| SCHEMBL7281348 | 0.81 | CA12 (0.69) | CA12CA9ELANECA2CA1 | |
| SCHEMBL356403 | 0.81 | CA12 (0.69) | CA12CA9ELANECA2 | |
| SCHEMBL8865776 | 0.81 | CA12 (0.69) | CA12CA9ELANECA2CA1 | |
| SCHEMBL5899155 | 0.81 | ELANE (1.00) | CA12CA9ELANECA2CA1 | |
| SCHEMBL7290946 | 0.81 | CA12 (0.69) | CA12CA9ELANECA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1274781-B1 | POLYCARBONATE COMPOSITION RESISTANT TO GAMMA RADIATION | BAYER AG (US) | 2004-12-15 | — | — | EP | claimed |
| WO-2023166039-A1 | INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR Lasß | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2023-09-07 | — | — | WO | disclosed |
| US-20160244435-A1 | EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-08-25 | — | — | US | disclosed |
| US-20130184258-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184258-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-18 | — | — | US | disclosed |
| EP-2316831-B1 | 2-(morpholin-4-yl)pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer | NOVARTIS AG (CH) | 2013-03-06 | — | — | EP | disclosed |
| US-8309543-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309543-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120238578-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120238578-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
| US-7459016-B2 | Method for the production of phthalocyanine pigment preparations | CLARIANT PRODUKTE (DEUTSCHLAND) GMBH (DE) | 2008-12-02 | — | — | US | disclosed |
| US-7423148-B2 | Small molecule PI 3-kinase inhibitors and methods of their use | CHIRON CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423148-B2 | Small molecule PI 3-kinase inhibitors and methods of their use | CHIRON CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| US-7279514-B2 | High-molecular-weight polymeric material comprising diketopyrrolopyrrole pigments | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279514-B2 | High-molecular-weight polymeric material comprising diketopyrrolopyrrole pigments | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279444-B2 | Substituted benzoylpyrazoles | BAYER CROPSCIENCE GMBH (DE) | 2007-10-09 | — | — | US | disclosed |
| US-7279444-B2 | Substituted benzoylpyrazoles | BAYER CROPSCIENCE GMBH (DE) | 2007-10-09 | — | — | US | disclosed |
| US-7255734-B2 | Phthalocyanine pigment preparations | CLARIANT PRODUKTE (DEUTSCHLAND) GMBH (DE) | 2007-08-14 | — | — | US | disclosed |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-02-02 | — | — | US | disclosed |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238578-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | SCNN1G, KCNN3, KCNN2 | CA12 2428/4885CA9 1929/4885ELANE 2497/4885 |
| US-20160244435-A1 | EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS | NQO1, TXN2, MPO | CA12 4729/4885CA9 4167/4885ELANE 14/4885 |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | SCNN1G, KCNN3, KCNN2 | CA12 2428/4885CA9 1929/4885ELANE 2497/4885 |
| US-20130184258-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | SCNN1G, KCNN3, KCNN2 | CA12 2428/4885CA9 1929/4885ELANE 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.